Signaling downstream of GM-CSF and IFN-γ involves the JAK-STAT pathway, and the efficacy of JAK inhibitors is widely recognized in RA (102), which raises expectations for the treatment of LVV (103). This evidence concerns the gene IFNG and rheumatoid arthritis.